AU2003224132A8 - Effective sirna knock-down constructs - Google Patents

Effective sirna knock-down constructs

Info

Publication number
AU2003224132A8
AU2003224132A8 AU2003224132A AU2003224132A AU2003224132A8 AU 2003224132 A8 AU2003224132 A8 AU 2003224132A8 AU 2003224132 A AU2003224132 A AU 2003224132A AU 2003224132 A AU2003224132 A AU 2003224132A AU 2003224132 A8 AU2003224132 A8 AU 2003224132A8
Authority
AU
Australia
Prior art keywords
effective sirna
sirna knock
down constructs
constructs
knock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003224132A
Other versions
AU2003224132A1 (en
Inventor
Gerardus Johannes Francis Arts
Mark Jacques Yvonne Lambrecht
Kristina Djokic
Remko Johannes Clasen
Emir Mesic
Sandra Griffioen
Carolina Johanna Leonard Bergs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schueren Jan V D
Galapagos Genomics NV
Original Assignee
Schueren Jan V D
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schueren Jan V D, Galapagos Genomics NV filed Critical Schueren Jan V D
Publication of AU2003224132A1 publication Critical patent/AU2003224132A1/en
Publication of AU2003224132A8 publication Critical patent/AU2003224132A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
AU2003224132A 2003-04-24 2003-04-24 Effective sirna knock-down constructs Abandoned AU2003224132A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/004362 WO2004094636A1 (en) 2003-04-24 2003-04-24 Effective sirna knock-down constructs

Publications (2)

Publication Number Publication Date
AU2003224132A1 AU2003224132A1 (en) 2004-11-19
AU2003224132A8 true AU2003224132A8 (en) 2004-11-19

Family

ID=33305624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003224132A Abandoned AU2003224132A1 (en) 2003-04-24 2003-04-24 Effective sirna knock-down constructs

Country Status (2)

Country Link
AU (1) AU2003224132A1 (en)
WO (1) WO2004094636A1 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
JP2006507841A (en) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
AU2003267347A1 (en) * 2003-09-10 2005-03-29 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
EP1709176A1 (en) * 2004-01-21 2006-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
JP4761389B2 (en) 2004-04-09 2011-08-31 株式会社ジーンケア研究所 Cancer cell-specific apoptosis inducer targeting genes related to chromosome stabilization
CA2605574A1 (en) 2004-04-20 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
EP2259063B1 (en) 2004-04-27 2012-05-23 Galapagos N.V. Compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
EP2270160A1 (en) 2004-06-14 2011-01-05 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
JP2008503712A (en) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ Methods and means for treatment of osteoarthritis
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
TWI386225B (en) * 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
WO2006108581A2 (en) * 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
US7897583B2 (en) 2005-05-24 2011-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPRU
EP1910570B1 (en) * 2005-07-29 2011-04-13 Oncotherapy Science, Inc. Gene and polypeptide relating to breast cancer
KR20070101610A (en) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
TW201336514A (en) 2006-04-13 2013-09-16 Alcon Res Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
JP5473594B2 (en) 2006-04-13 2014-04-16 アルコン リサーチ， リミテッド RNAi-mediated inhibition of histamine receptor H1-related conditions
US20100197763A1 (en) * 2007-05-02 2010-08-05 Merck & Co., Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2152870A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
US20100120895A1 (en) * 2007-05-02 2010-05-13 Merck & Co., Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2152875A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
CA2690685A1 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
US20110152345A1 (en) * 2007-08-24 2011-06-23 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
RU2010119775A (en) * 2007-11-09 2011-12-27 Айсис Фармасьютикалс,Инк. (Us) MODULATION OF EXPRESSION OF FACTOR 7
WO2010004051A1 (en) * 2008-07-11 2010-01-14 Medizinische Universität Innsbruck Antagonists of nr2f6 for augmenting the immune response
ES2343292B1 (en) * 2008-07-24 2011-06-20 Universidad Complutense De Madrid SIRNA AND SHRNA FOR THE ELABORATION OF MEDICINES AGAINST THE ELEVATED PRESSURE INTRAOCULAR.
CA2736425A1 (en) 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
EP2398479A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398481A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010094732A1 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
US20120004281A1 (en) * 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010115825A2 (en) 2009-03-31 2010-10-14 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
EP3043179B1 (en) 2009-04-01 2020-05-06 Galapagos N.V. Methods and means for treatment of osteoarthritis
EP2236607A1 (en) * 2009-04-02 2010-10-06 Sanofi-Aventis Use of inhibitors of St3Gla6 activity for modulation of adipogenesis
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
ES2629339T3 (en) * 2009-06-16 2017-08-08 Curna, Inc. Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011105901A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011163499A2 (en) 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2757152A4 (en) * 2011-09-14 2015-09-02 Nippon Kayaku Kk Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
RU2014119787A (en) 2011-10-25 2015-12-10 Айсис Фармасьютикалс, Инк. GCCR ANTI-SENSE REGULATION
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
KR20170142997A (en) * 2012-05-24 2017-12-28 아이오니스 파마수티컬즈, 인코포레이티드 Methods and compositions for modulating apolipoprotein (a) expression
JP2016522675A (en) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Molecular targets useful in the treatment of diseases associated with epithelial-mesenchymal transition and inhibitors of said targets
WO2014139883A1 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
DK3444350T3 (en) 2013-07-03 2022-02-07 Dicerna Pharmaceuticals Inc PROCEDURES AND COMPOSITIONS FOR SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN IN DOUBLE-STRANDED RNA
EP3960860A3 (en) * 2014-02-11 2022-06-08 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
WO2015171918A2 (en) * 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
WO2016164407A2 (en) * 2015-04-07 2016-10-13 Polyskope Labs Detection of one or more pathogens
AU2016259971B2 (en) * 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
ES2917181T3 (en) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Diacylglycerol acyltransferase 2 (DGAT2) modulators
CN105349665B (en) * 2015-11-27 2018-06-19 上海锐赛生物技术有限公司 Kit of colorectal cancer risk of recurrence and application thereof after assessment oxaliplatin chemotherapeutic
AU2017205462A1 (en) 2016-01-05 2018-06-07 Ionis Pharmaceuticals, Inc. Methods for reducing LRRK2 expression
WO2017207656A1 (en) * 2016-05-31 2017-12-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system
AU2018297262A1 (en) 2017-07-06 2020-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
TW201919647A (en) 2017-08-10 2019-06-01 華盛頓大學 Compositions and methods of treatment using nicotinamide mononucleotide
CN108387621B (en) * 2018-01-10 2019-11-26 暨南大学 Cadmium ion aptamer and screen printing electrode electrochemica biological sensor
WO2020006267A1 (en) 2018-06-27 2020-01-02 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing lrrk2 expression
CN109402117B (en) * 2018-11-07 2022-03-01 上海中医药大学附属曙光医院 Adeno-associated virus for silencing expression of mouse intestinal RASGRP1 and preparation method and application thereof
WO2020101880A1 (en) * 2018-11-14 2020-05-22 Oklahoma Medical Research Foundation Compositions and methods of treating systemic lupus erythematosus
US20230042436A1 (en) * 2018-12-03 2023-02-09 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2021206922A1 (en) * 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2022066847A1 (en) * 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en) * 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
KR20230150844A (en) 2021-02-26 2023-10-31 알닐람 파마슈티칼스 인코포레이티드 Ketohexokinase (KHK) iRNA compositions and methods of using the same
CN113430199A (en) * 2021-06-30 2021-09-24 武汉三鹰生物技术有限公司 Interfering sequence of HADHA mRNA and verification method thereof
WO2023114989A2 (en) * 2021-12-17 2023-06-22 University Of Massachusetts Oligonucleotides for mlh3 modulation
WO2023154964A1 (en) * 2022-02-14 2023-08-17 Alloy Therapeutics, Inc. Methods and compositions for targeting efemp1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416445A1 (en) * 2000-07-19 2002-01-24 Exelixis, Inc. Human rrp sequences and methods of use
WO2003012052A2 (en) * 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs

Also Published As

Publication number Publication date
WO2004094636A1 (en) 2004-11-04
AU2003224132A1 (en) 2004-11-19

Similar Documents

Publication Publication Date Title
AU2003224132A8 (en) Effective sirna knock-down constructs
PL1807520T3 (en) Rna constructs
EP1765074A4 (en) POSITIONALLY MODIFIED siRNA CONSTRUCTS
GB2420282B (en) Lotioned tissue product with improved stability
IL174848A0 (en) Nucleic acid constructs
IL172988A0 (en) Bioreactor
IL185315A0 (en) Rnai expression constructs
IL169909A0 (en) Knock-down drums
AU2003237303A8 (en) Aptamer constructs
EP1707062A4 (en) Fermented food
EP1687398A4 (en) Hiv-dependent expression constructs and uses therefor
GB2408702B (en) Bioreactor
GB0423659D0 (en) RNA constructs
SI2229956T1 (en) Multimeric constructs
GB0320548D0 (en) Supports
AU2003901418A0 (en) Sirna
GB0313558D0 (en) Easy strimmer
GB0328797D0 (en) Easy klik
GB0312042D0 (en) Bioreactor
GB0315183D0 (en) Bioreactor
PL114016U1 (en) Small armchair-potty
GB0722959D0 (en) Stable intergrands
AU156363S (en) Heater
AU156722S (en) Heater
AU156246S (en) Heater

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 49, PAGE(S) 10021 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME GALAPAGOS GENOMICS N.V., APPLICATION NO. 2003224132, UNDER INID (71) CORRECT THE NAME TO READ GALAPAGOS GENOMICS N.V.; VAN DER SCHUEREN, JAN

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase